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	Flavonoids are naturally occurring compounds that are consumed regularly in the diet. The property of flavonoids, which they are most commonly known for, is their antioxidant activity. Other potential pharmaceutical applications of flavonoids can be related to their enzyme inhibition, anti-allergic, anti-inflammatory, anti-microbial and anti-cancer properties. Lipases have been used effectively in the production of flavonoid ester derivatives that have shown both increased antioxidant and antimicrobial activity. Enzymatic esterifications of flavonoids are performed in organic solvents that increase substrate solubility of complex organic molecules.

For the esterification of compounds in non-aqueous reaction conditions, vinyl esters are often preferred as substrates compared to carboxylic acids (which can be involved in reversible reactions, due to the formation of the by-product, water). In this study a group of vinyl esters of tert-butoxycarbonylated amino acid derivatives were synthesized to study alongside a range of commercially available vinyl esters.
   
The synthesis of ester derivatives of naringin using a range of hydrolytic enzymes has been studied. A range of small to medium sized commercially available vinyl esters (C2- C10), as well as amino acid vinyl esters were selected for the biotransformations. For the esterification of naringin, small-scale reactions were carried out for 72 hrs and the reaction mixtures were analysed by HPLC. Lipases from the species Pseudomonas stutzeri, Candida antarctica and Alcaligenes spp. performed more than 80% conversion of naringin with some of the selected acylating agents. Reactions carried out with P. stutzeri lipase were scaled up to isolate the product of the biotransformation. None of the screened enzymes were successful in the acylation of naringin with the amino acid vinyl esters.

Assays were carried out to compare the antioxidant activity of naringin and the synthesized derivatives. Two of the acyl derivatives showed a greater antioxidant activity in the reduction of Cu2+, compared to naringin.

Aminoglycosides are antibiotics that have anti-bacterial properties. As well as their anti-bacterial properties some have been employed for their ability to suppress stop codons, which is a useful property in reducing symptoms of some hereditary disorders. 
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1.1.1 Applications of Biocatalysis

The synthesis of organic molecules using an enzymes catalysts is called a biotransformation. In recent years there has been an increase in the use of biotransformations, especially in the pharmaceutical industry. Biotransformations of organic molecules are not restricted to isolated enzymes, as reactions can been catalysed by other biological systems including whole-cells and specific catalytic antibodies.

Enzymes have evolved for millions of years to function in physiological systems. Enzymes have the ability to increase the rate of a reaction, usually by 108-1010 compared to the non-enzymatic (Menger, 1993). The working conditions of enzymes are usually within a pH range of 5-8 and at mild temperatures. If the ideal working conditions are known  an enzyme’s activity can be optimised. 

A disadvantage of using enzymes as catalysts for organic synthesis is that they  have evolved to have optimal activity in aqueous solvents. Enzyme-catalysed synthesis in organic solvents usually occurs at a lower rate in the absence of water. Aqueous reaction media in organic synthesis has its restrictions due to the high boiling point of water and the low solubility of complex organic compounds. (Klibanov, 1997). 





1.1.2 Biocatalysis in Non-Aqueous Media

Some enzymes have the ability to catalyse reactions in non-aqueous solvents which can be chemoselective, regioselective and enantioselective of a wide range of substrates. The use of enzymes in organic solvents is ideal for overcoming thermodynamic restrictions, which occur in the presence of water (e.g. the hydrolysis of an ester). Another advantage for the use of organic solvents is increased substrate concentration, as larger naturally occurring compounds are mainly hydrophobic molecules that are usually more soluble in non-aqueous solvents (Khmelnitsky and Rich, 1999). Hydrolytic enzymes such as lipases, esterases and proteases under non-aqueous reaction conditions are used as biocatalysts, as they show the highest activity (Dordick, 1989).

To assess the affect of non-aqueous media on enzyme activity, the structure of the protease subtilisin Carlsberg (SC) was determined in water, acetonitrile and dioxane by X-ray crystallography (Schmitke et al., 1997). The enzyme had little structural variation when dissolved in water, compared to when dissolved in acetonitrile or dioxane. This was further supported with similar results seen when subtilisin was dissolved in organic media. Fourier-transform infrared spectroscopy (FTIR) showed that the secondary structure of subtilisin was not affected by numerous organic solvents including octane, hexane, carbon tetrachloride, butyl ether, toluene, tert-amyl-alcohol, ethyl ether, THF, acetonitrile and dioxane (Griebenow and Klibanov, 1997). 

In a separate study the catalytic activity of subtilisin was investigated using FTIR, to assess the enzyme’s secondary structure in the neat organic solvents glycerol, 2,2,2-trifluoroethanol, 2,2,2-trichloroethanol and DMSO. In this case the organic solvents appeared to denature the enzyme, reducing the catalytic activity (Xu et al., 1997). However despite alterations in the secondary structure of subtilisin, a larger degree of protein denaturation occurs in the lyophilisation step. Dehydration of the protein is more likely to reduce catalytic activity rather than interactions with organic solvents (Klibanov, 1997).

The catalytic properties of an enzyme are dependent upon the pH of its working solvent due to the ionisation of amino acid functional groups: amine, carboxyl, guanidinyl, imidazole, phenolic and sulphide groups. In organic solvents lyophilised proteins exhibit a pH memory (Costantino et al., 1997). This is when an enzyme is lyophilised in an aqueous solution at the pH where optimum activity is observed, due to the ionisation of amino acid functional groups (Klibanov, 1989). The optimum activity of the enzyme can then be similarly observed in an organic solvent. The pKa values of the amino acid carboxyl, amino and phenolic groups were calculated by the use of FTIR (Costantino et al., 1997). This showed that there was little variation in the pKa values of the native enzyme and the lyophilised protein functional groups in aqueous solution. This means lyophilisation has little effect upon enzyme ionisation, which is dependent on the previous environment. 

A technique used to activate enzymes in organic solvents is salt-induced activation. The activity of an enzyme is increased in organic solvents, by increasing the polarity of its active site (Affleck et al., 1992). One example is the addition of KCl during the lyophilisation of the enzyme subtilisin, increasing the activity of the enzyme by 3700-fold (Khmelnitsky et al., 1994). Salt-induced activation of the enzyme thermolysin has been used in the biotransformation of the natural product (and anti-cancer drug) paclitaxel (38), to form acyl derivatives (Khmelnitsky et al., 1997). The salt-induced activation of the enzyme led to a 20-fold increase in activity compared to that of the native thermolysin. The specific mechanism of the salt at the active site is unknown. The catalytic efficiencies of salt induced lyophilised enzymes can be increased with freeze drying time and decreasing water content to an optimum (Ru et al., 1999).

Another technique used to activate enzymes in organic solvents is ion-pair solubilisation. Enzymes are unable to work at high rates in organic solvents as they dissolve poorly (or not all). The presence of lipids and surfactants, create the formation of hydrophobic ion pairs, increasing both the stability and solubility of the enzymes in organic solvents. (Wagnikar et al., 1997; Mori and Okhata, 1997). This technique was used to increase the activity of a lipase, in the (ring opening) polymerisation of pentadecalactone. In the presence of surfactant the rate of the enzyme-catalysed reaction was 100-fold that of the native enzyme in non-aqueous media (Noda et al., 1997).







	The hydrolase enzyme family has been studied extensively in terms of their structure and mechanism. It is a large family of enzymes and is responsible for catalysing the hydrolysis of bonds. They are known to cleave a range of bonds including esters, lactams, nitriles and amides. The majority utilise a catalytic triad that consists of a nucleophilic serine or cysteine, an acidic residue and a basic residue. These were first described by Blow et al., (1969). Due to the organic solvent tolerance of most hydrolytic enzymes, they have been developed into tools for organic synthesis. 

Studies into the structural features of this enzyme family have identified a conserved α/β hydrolase fold (Ollis et al., 1992). Crystallographic investigations have shown that many of the hydrolytic enzymes are serine hydrolases. These contain a catalytic triad with a nucleophilic serine residue found in a conserved pentapeptide sequence (Gly-X-Ser-X-Gly) (Brenner et al., 1988). This sequence is termed the nucleophilic elbow, located on a turn between a β strand and an α helix. This positions the nucleophile for the approach of the substrate and water molecule.







Lipases are one of the most commonly used enzymes in biotransformations, as they can be obtained at a low cost, are stable in organic solvents and do not require cofactors to work efficiently. When carbohydrate molecules are the substrate compounds, lipases can be utilised for their regioselectivity towards different hydroxyl groups in polyhydroxylated molecules. Lipases can catalyse hydrolysis reactions or can alternatively be used to synthesize ester and amide bonds.

When lipases are carrying out transesterification reactions in organic solvents, alcohol groups replace water as the nucleophile in the reaction. In the active site a serine residue, which is a member of the catalytic triad, is activated to form an acyl-enzyme derivative with the acyl donor (after an initial tetrahedral transition state) (Blow et al., 1969). In most cases the preferred acyl donor is a vinyl ester. Vinyl esters are more commonly used due to the formation of the by-product, vinyl alcohol (2), which is almost irreversibly converted to acetaldehyde (1) (which is non-nucleophilic). This drives the acylation reaction to completion (Faber, 1996). The alternative use of carboxylic acids as acyl donors, leads to the production of water as a by-product.  The presence of water in the reaction vessel can lead to the reversible hydrolysis reaction in the presence of a lipase. After the release of the vinyl alcohol (2), a second tetrahedral transition state is formed with the nucleophilic alcohol substrate. This is followed by cleavage of the acyl bond and the diffusion of the acyl product from the active site. (Figure 1.1).






Figure 1.1. A diagrammatic representation of the esterification reaction mechanism occurring in the active site of lipase enzymes.


	Another example where primary hydroxyl groups of carbohydrates have been acylated in preference to secondary hydroxyl groups is lipase-catalysed reactions of furanose and pyranose derivatives (Hennen et al., 1988). 4-Methyl furanosides and their peracetylated derivatives were used as the substrates for acylation reactions. The reactions were carried out in THF and the acylating agents used were isopropyl acetate and trichloroethyl acetate. Yields of up to 77% for the conversion of the substrates to acylated products were achieved with the use of the porcine pancreatic lipase (PPL). Similar yields of acylation were seen with a lipase from a Pseudomonas species. For the acylation of pyranose compounds, conversion yields of up to 100% were achieved when using PPL and CALB. For all acylation reactions of pyranose and furanose derivatives the the lipases were regioselective for the primary hydroxyl group.












Figure 1.2. Structures of 6-O-acylated derivatives of (a) glucopyranose (4), (b) galactopyranose (5) and (c) mannopyranose (6), which are acylated at secondary hydroxyl groups (adapted from Bashir et al., 1995).   







Figure 1.3. The acylation of digitonin (7) occurs at the 4’-OH secondary hydroxyl group, despite the primary hydroxyl group at the 6-OH position. This is due to the 6-OH being sterically hindered (adapted from Danieli et al., 1999).


Lipases can also carry out regioselective deacylation reactions in non-aqueous reaction media. One example is their use in the synthesis of the natural product acetophenone. The enzymes PPL and Candida cylindracea lipase (CCL) have both been used to catalyse a hydrolysis deprotection reaction of acetophenone precursors (8-18). The hydrolysis reaction of the para acetoxyl group (to the carbonyl function) predominates in various organic solvents including acetone and acetonitrile. The lipases are regioselective for the para acetoxyl group, as this lies closest to the serine residue in the active site during (Figure 1.4) (Parmar et al., 1992).








Proteases are able to catalyse acylation reactions of polyhydroxylated molecules, so are often screened alongside the lipases. When screening proteases in organic solvents they often show higher activity in the solvent DMF. In particular the alkaline proteases from Streptomyces species have been found to be highly active in this solvent (Shibatani et al., 1997; Kitagawa et al., 1999). 






Figure 1.5. Scheme showing the enzymatic synthesis of vinyl uridine esters and polymerisation (adapted from Fan et al., 2004).






Figure 1.6. Scheme showing the biocatalytic preparation of different doxorubicin derivatives (25-27), when using vinyl butyrate (24) as an acyl donor and different preparations of the protease subtilisin Carlsberg (adapted from Altreuter et al., 2004).  
The addition of KCl to the lyophilisation preparation (salt activation), allows for further acylations of the 4’-OH (26) and 3’-NH2 (27) of the sugar group. Two 14-OH derivatives tested against the MCF7 breast cancer cell line showed greater cytotoxcity than doxorubicin (23) (Altreuter et al., 2004).

Derivatives of doxorubicin (23) with increased cytotoxicity towards cancer cells have also been synthesized using a synthetic approach. These derivatives have been produced by the alkylation of the sugar group (Farquhar et al., 1998).

	The application of proteases can be limited in comparison to lipases due to their high substrate specificity (Faber, 1996; Sears and Wong, 1996). Combined site directed mutagenesis and chemical modification of Bacillus lentus subtilisin has been used to create a protease that has greater activity than the wild type enzyme (Berglund et al., 1997). The enzyme was altered with the combined approach of site directed mutagenesis introducing cysteine residues, which were then modified with methanethiosulfonate reagents. This double-approach creates new enzyme activity, by the introduction of unnatural amino acid side chains (Dickman et al., 1998). Results showed that the Asn62Cys-S-CH3 and Met222Cys mutant are better catalysts than the wild type enzyme. In the case of the Met222Cys mutant, a large methionine is replaced by a smaller cysteine residue at the boundary between the two pockets, where nucleophiles approach the acyl-enzyme intermediates in the active site. The reduction of steric hindrance increases enzyme activity (Dickman et al., 1998). 

	Acylation reactions using the proteolytic subtilisin enzyme, can be carried out in the presence of a small proportion of buffer in the reaction mixture, as well as triethylamine. The additive triethylamine has increased the reaction yields of some subtilisin catalysed reactions. The introduction of a base into the reaction mixture can also neutralise unwanted acidic species (Kise et al., 1988; Yamamoto and Kise, 1993). This method has been used to synthesize the malignant melanoma cell specific antigen, diasialoganglioside 9-O-acetyl GD3 (30) (Takayama et al., 1996). This was carried out  by  the  acetylation  of  GD3’s (28)  N-acetylneuraminic acid group with vinyl acetate (29) using subtilisin (Figure 1.7). The concentration of triethylamine in the reaction mixture is an important factor. At a low concentration the reaction occurs at a slow rate, while at higher concentrations multiple acetylations of GD3’s (28) hydroxyl groups occurs.






1.1.4 Biocatalysis in the Synthesis of Pharmaceutical Compounds

The application of enzymes in the pharmaceutical industry is continually expanding. The potential use of enzymes is ideal due to their chemo-, stereo- and regioselectively for a substrate. Enzymes have been used to synthesize drug molecules on both a large industrial scale and a laboratory scale synthesis. 

	Ibuprofen (31), naproxen (32), ketoprofen (33), flurbiprofen (34) and ketorolac (35) (Figure 1.8) are all examples of non-steroidal anti-inflammatory drugs (NSAIDS) that have been synthesized using a biotransformation approach in at least one step of their manafacture. One example is the application of CCL, which hydrolyses the ester precursor of naproxen, to produce enantiomeric pure (S)-naproxen (32) (the medicinally active compound) (Wu et al., 1990).  

Paclitaxel (38) is a chemotherapeutic drug (Rowinsky et al., 1990) isolated from the bark of Pacific Yew (Kingston, 1994) that can also be synthesized on both a laboratory and industrial scale. It can be produced in high yields of the active enantiomeric form on a laboratory scale, using CALB to catalyse an acylation reaction in the later stages of synthesis. This biotransformation produces a 90% yield of the active enantiomeric form of paclitaxel (38)  (Nicolaou et al., 1994).


Figure 1.8. A diagram showing NSAIDS that have been synthesized using a biocatalyst (adapted from Zaks and Dodds,1997).







Figure 1.9. Scheme showing the resolution of the racemic precursor azetidinone acetate (36), which can be carried out using lipases from two different Pseudomonas species (adapted from Zaks and Dodds, 1997).






















1.2.2 Structure of Flavonoids














Naringin (43) (Figure 1.12) is a conjugate of a sugar molecule (D-glucose and L-rhamnose) with naringenin that is found in grapefruit juice. It is the presence of naringin (43) in citrus fruits that gives them their distinctive bitter taste.  It is an ideal natural product to manipulate as it has many pharmaceutical applications. These include anti- microbial (Ng et al., 1996), anti-hypercholesteremic (Jeon et al., 2004), anti-cancer (Marchand et al., 2000) and anti-inflammatory (Balestrieri et al., 2003) properties.






Figure 1.12. A diagram showing the structure of the flavonoid naringin (43). 


Naringin’s (43) ability to inhibit LDL (low-density lipoproteins) oxidation and platelet aggregation creates an anti-hypercholesteremic effect (Cooks and Samman, 1996). The oxidative modification of LDL produces lysophosphatidylcholine that accumulates in LDL. This accumulation of lysophosphatidylcholine has various adverse effects on vascular tissue. The effect of naringin (43) in vivo was studied when feeding rabbits a high cholesterol diet supplemented with the flavonoid. The effect of naringin (43) was to lower the LDL and cholesterol levels compared to the control group of rabbits who were not taking the supplement (43). The effect of naringin (43) is to down-regulate the activity of the enzyme acyl-CoA: cholesterol acyltransferase (ACAT), a cholesterol-regulating enzyme that is involved in cholesterol homeostasis (Jeon et al., 2004). High cholesterol levels in the body have previously been associated with the up regulation of ACAT (Garcia-Gonzalez et al., 1992). Naringin (43) supplementation also accounts for a higher cholesterol concentration in the faeces, but the exact mechanism is unknown (Jeon et al., 2004).





1.2.4 Biotransformation of Flavonoids

The use of flavonoids as medicinal agents has been restricted due to their low-solubility. Flavonoids are largely insoluble in both aqueous and fatty media, so their delivery to human tissue is largely restricted. Chemical techniques, as well as biocatalytic approaches can be used in order to modify the solubility of these flavonoids. An example of a chemical approach used to modify the solubility of a flavonoid, are the complexing of hesperetin and naringenin with β-cyclodextrin. These derivatisations lead to an increase in the water solubility of these compounds (Tommasini et al., 2004). 

The modification of flavonoids using a biotransformation approach has been focused on acylation and glycosylation reactions. Glycosylation of flavonoids occur naturally during their biosynthesis in plants, as they are secondary metabolites. These glycotransferases, transfer sugar groups to the flavonoid molecules, which act as sugar acceptors (Mackenzie et al., 1997). Xanthomonas campestris is a bacterium that expresses a glycotransferase, which is able to glycosylate flavonoids (Kim et al., 2007). This   glycotransferase  showed  activity  towards  the hydroxyl  group at  the  C’3  position  of   the  B  ring   (Figure   1.13)  of  the   flavonoids  fisetinn (44),   gossypetin (45),   luteolin (46) and  quercetin (47). For the conversion of luteolin to the glycosylated derivative, 100% conversion was measured. The reaction was regiospecific, as glycosylation occurred at the 3’-OH position, instead of the 4’-OH group of the B ring.

Glycosylation biotransformations can also be used to extend the number of sugar units of a flavonoid. One example is the addition of a further glycosyl unit to a rutin (48) molecule to form 4-α-D-glucopyranosyl-rutin (49). A glycotransferase from Bacillus stearothermophilus was employed to transfer an additional sugar to the molecule in a solution of 50% aqueous methanol at 20 °C.  The reaction is regioselective  for  the 4-OH  of  the glycosyl unit,  so  that  the  second  glucose  unit  is 


Figure 1.13. A diagram showing the preferred site of flavonoid glycosylation at the C’3 hydroxyl group of the B-ring (adapted from Kim et al., 2007).









Figure 1.14. Scheme showing the glycosylation of rutin (48) by a transglycosylation enzyme from B. stearothermophilus (adapted from Suzuki and Suzuki, 1991).

Another area of focus has been the lipase-catalysed acylation of flavonoids. This type of biotransformation allows the lipophilic nature of the molecule to be increased, by the addition of a fatty acid. Biocatalytic acylations of flavonoids have been carried out by the use of lipases and proteases in non-aqueous media. The relative successes of enzymes carrying out these reactions are dependent on various factors in the reaction mixtures. These include temperature, reaction solvents, by-products, the nature of the acyl donor and the nature of the flavonoid (Chebil et al., 2006).
 
The enzymes are regioselective for the hydroxyl group in flavonoid compounds. The biocatalytic approach of flavonoid derivatisation of hydroxyl groups is a more useful tool than using a chemical approach. The chemical acylations of flavonoids are indiscriminate towards the hydroxyl groups of the flavonoid, which leads to a reduction in the antioxidant activity. Of particular biological importance is the hydroxyl group at the C’3 position of the B ring, which exerts a large proportion of the flavonoids ability to scavenge free-radicals (Rice-Evans et al., 1996).

Temperature is an important factor when carrying out any biotransformation, as at high temperature enzymes become denatured. Lipase biotransformations can be carried out at extreme temperatures from as low as –40 °C (Sakai et al., 1998) up to temperatures of 100 °C (Bornscheuer et al., 1992), depending on the source and stability of the enzyme. High temperature biotransformations have successfully been carried out for flavonoids, but are determined by the reaction conditions (Chebil et al., 2006). CALB has been used to successfully carry out full conversion of the flavonoid phloridzin to the cinnamate derivative at 100 °C. This temperature was more favourable for the reaction rate, than when carried out at 80 °C and 60 °C (Enaud et al., 2004).

The solvent used for flavonoid biotransformations are dependent on the nature of the substrates donor, as well as the enzyme being used. Flavonoids are polar molecules, so a polar organic solvent is usually employed to ensure that they dissolve. These solvents can often have the effect of stripping the functional waters from the enzyme that maintain its structure (Gorman and Dordick, 1992; MacNaughtan et al., 1993). 

The water content in the reaction mixture is very important in determining the direction of the reaction equilibrium, between esterification and ester hydrolysis (Dordick, 1989). The effect of water on the equilibrium is different for each enzyme and can also be influenced by the method of enzyme preparation (e.g. immobilisation) (Arroyo et al., 1999). The by-product of flavonoids acylations when using vinyl esters as substrate is vinyl alcohol (2). This by-product tautomerizes to form acetaldehyde (1) that can react irreversibly with lysine residues in the enzymes. This does not generally create a large problem in biocatalysis if an excess of enzyme is used (Schudok et al., 1997).





1.2.5 Biotransformations of Naringin

The regioselective acylation of naringin (43) was proposed based on lipase-catalysed acylations carried out on a similar compound, isoquercitin (50) (Nakajima et al., 1999). Figure 1.15 shows the lipase-catalysed reaction scheme for the production of isoquercitin-cinnamate (52), using vinyl cinnamate (51) as the acyl donor. When using CALB in the solvent acetone a yield of 68% was achieved for the isolated isoquercetin cinnamate ester, when the biotransformation was carried out at 37 °C for 168 hrs. This lipase-catalysed reaction was reproduced with various lipases and reaction solvents (including acetone and acetonitrile). The method used for the acylation of isoquercitin (50) could be applied to other similar flavonoid glycosides such as naringin (43). The acylation of naringin (43) is an ideal reaction to increase the solubility of the flavonoid, as naringin (43) has poor solubility in non-polar solvents and water, which makes its pharmaceutical potential limited (Patti et al., 2000).






Figure 1.15. Scheme showing the lipase-catalysed acylation of isoquercitin (50) (adapted from Nakajima et al., 1999).


Lipase-catalysed acylations of naringin (43) have also been carried out using CALB and three fatty acids: octanoic (C8), decanoic (C10) and dodecanoic acid (C12) (Kontogianni et al., 2003). A range of different solvents were screened for their suitability in the lipase-catalysed reactions.  Successful biotransformations of naringin (43) to the ester derivative were carried out in the presence of the solvents acetone, THF and tert-butanol. Acetone and tert-butanol gave the largest conversions of naringin (43) with the fatty acids, at 45 °C over 45 hrs. CALB was able to catalyse 30% conversion of naringin (43) in acetone and 20% in tert-butanol when octanoic acid was the acyl donor. These compared favourably to the use of THF in the reaction media, which gave less than 5% conversion yield. A similar trend was seen when decanoic and dodecanoic acid were used as acyl donors. 

Another important factor in the acylation of naringin (43) is the concentration of the acyl donor used in the reaction (Kontogianni et al., 2001; Mellou et al., 2005). In reactions with fatty acids, results suggested that as the concentration of the acyl donor is increased so do the initial reaction rates and conversion yields. The acylation of naringin (43) in this investigation was carried out using CALB in tert-butanol at 45 °C over 225 hrs. The largest conversion of naringin (43) (62%) was observed for the highest concentration of decanoic acid used (300 mM), while the lowest concentration of decanoic acid (50 mM), only gave a conversion of 27% under the same reaction conditions (Kontogianni et al., 2001). This trend, as expected is also seen when naringin (43) has been derivatised with C10 and C12 fatty acids and vinyl fatty acid esters. By increasing the acyl donor concentration the equilibrium is being shifted in the direction of the esterification reaction, therefore more derivatives are produced (Mellou et al., 2005). 

Biotransformations of naringin (43) have also been successfully carried out, using an ionic liquid as the reaction media (Katsoura et al., 2006). Various lipases have been used to derivatise naringin (43) with the acyl donors vinyl laurate and vinyl butyrate (24) in the ionic liquids 1-butyl-3-methylimidazolium tetrafluoroborate ([bmim]BF4) and 1-butyl-3-methylimidazolium hexafluorophosphate ([bmim]BF6), producing naringin-6’-O-laurate and naringin-6’’-O-butyrate (53) respectively (Figure 1.16). The conversion yield of naringin (43) when using CALB at 60 °C in [bmim]BF6 over 100 hrs was 63% with the acyl donor vinyl butyrate (24). In the ionic liquid [bmim]BF4 CALB gave a conversion yield of 62%. The enzyme Thermomyces lanuginosus lipase showed a higher conversion yield of naringin (43) under the same reaction conditions, producing a 77% conversion in [bmim]BF4. This enzyme did not produce a similar conversion yield in [bmim]BF6, as it was lower than that of the CALB catalysed reaction. 

For the derivatisation of flavonoids in ionic liquids, the conversion yields and the initial rates of reaction are dependent on a range of variables including the ionic liquid selected. Other variables which affect the yield and initial rate include water content, the incubation temperature, solubility and the concentration of substrates (factors which affect the rate and yield of the reaction in organic solvents). ([bmim]BF4) in particular has been shown to be a good alternative to organic solvents, due to its increased solubility of flavonoids (up to eleven times higher than in organic solvents). This increased solubility has resulted in higher yields of acylated derivatives in single step biotransformations of flavonoids (Katsoura et al., 2007).




























1.3 Spinal Muscular Atrophy 


1.3.1 Spinal Muscular Atrophy 

Spinal muscular atrophy (SMA) is an autosomal recessive disorder that is associated with the neuronal degeneration of a child (as it has an early age of onset). Sufferers of SMA have symptoms of progressive muscular weakness and in the more severe forms of the disorder; the final outcome in patients is death (Iannaccone, 1998). The severity of the symptoms in sufferers and the age of onset have led to three different classifications of the disorders. Type 1 is the acute form of the disorder and is associated with sufferers of severe symptoms. From birth the symptoms manifest with initial muscle weakness and the sufferer usually dies before the age of two years old. Type 2 form of the disorder has a later age of onset (after 6 months) and individuals usually live longer than type 1 sufferers and develop symptoms of general muscular weakness. Type 3 sufferers have proximal muscle weakness that they develop at a later age of onset of about 18 months. These have the least severe symptoms and despite general weakness they usually achieve the ability to walk.

The SMA disorder was mapped to the locus position 5q13, when compared to non-sufferers by genetic analysis. The analysis revealed inverted duplication as a result of unequal crossing over of chromosome 5, in a region of approximately 500 kb. A critical region of 140 kb is deleted within the telomeric region of the chromosome in sufferers (Lefebvre et al., 1995). This region contains a gene encoding for a 294 amino acid protein, SMN. Mutations or deletions of this gene lead to the development of SMA.

Humans have two copies of the SMN gene. The deleted or mutated form of the SMN 1 gene leads to the development of SMA. The SMN 2 gene is also found on the same chromosome, but is unable to produce significant amounts of the SMN protein, to prevent the onset of the disorder. There is only a five nucleotide difference between the genes of each form of the SMN protein (Lefebvre et al., 1995), which leads to exon 7 being spliced out in SMN 2. This means that despite the production of SMN 2, SMA still manifests in individuals lacking a functional SMN 1 gene (Lorson et al., 1999).





1.3.2 SMN and Aminoglycosides

SMN can be identified in the cytoplasm and the nucleus of cells as they form bodies known as gems (Liu and Dreyfuss, 1996). These are multiprotein complexes of SMN plus other proteins involved in its cellular activities. The other proteins within this complex have arginine and glycine rich domains, which firstly encourage the binding of the SMN and possibly the assembly of the small nuclear ribonucleoproteins (snRNPs) and protein splicing factors (Friesen and Dreyfuss, 2000).

The SMN protein has several conserved regions that have been investigated, which identify its properties. For example exon 6 contains the most conserved region of the protein, a Y-G box. Missense mutations suggest that exon 6 is critical for SMN function (Ogino and Wilson, 2002). Exon 7 is not highly conserved, which seems unusual since as previously described its absence in the SMN protein appears to result in the development of the SMA disorder (SMNΔ7 protein). A five amino acid sequence has been identified in human SMN as Gln-Asp-Glu-Lys-Glu that is necessary for the export of SMN from the nucleus to the cytoplasm (Zhang et al., 2003). These findings implicate that exon 7 is necessary for SMN export from the nucleus to the cytoplasm and a possible targeting defect could lead to SMA in neuronal cells.

Functions of the various exons have been investigated by producing constructs of the protein containing different exons (Hua and Zhou, 2004). These identified multifunctions of the protein in both the nucleus and the cytoplasm. When a random sequence was attached to a construct of exon 1-6 (as few as five amino acids), it was sufficient to export the SMN protein to the cytoplasm. This led to the belief that exon 6 and 7 coordinate the distribution of SMN, through the exon 6 motifs and the non-specific carboxy sequence of exon 7.

Those who suffer from SMA, only express the SMN 2 gene. Only 10% of the protein is functional and the other 90% of the expressed protein lacks the exon 7 (Lefebvre et al., 1995). This difference in the translated proteins is due to the previously mentioned splicing of exon 7 in SMN 2, which is caused by a single nucleotide difference between the two genes (Lorson et al., 1999). This base change in exon 7 has been identified as a C to T transition. This mutation is responsible for the disruption of an exon splicing enhancer. These are cis elements that can be found within the target exon. They are purine rich sequences necessary for recognition of exons and act as binding sites for the SR proteins that carry out the splicing (Berget, 1995).

This nucleotide difference reduces the activity of the enhancer and effects alternative splicing activity, resulting in the majority of the SMN 2 transcript lacking the exon 7 of the SMN protein (Monani et al., 1999). SMA patients produce only the SMN 2 and not the SMN 1 protein, so the change in this enhancer site leads to an insignificant level of full length SMN. This leads to the development of SMA in sufferers, as SMN 2 is unable to compensate the loss of SMN 1.

Various strategies have been used to try and treat SMA. These have involved both pharmaceutical and genetic approaches. One particularly interesting potential approach has been the use of the antibiotics aminoglycosides. The aminoglycosides work by causing the read through of the primary stop codon in exon 8 of the SMN 2 transcript (Wolstencroft et al., 2005). This approach has been able to suppress stop codons, which can be used to combat some genetic disorders. Examples of aminoglycosides being applied for the suppression of stop codons are for the treatment of cystic fibrosis, Duchenne muscular dystrophy (Barton-Davis et al., 1999), mutated V2 vasopressin receptor (Sangkuhl et al., 2004), ataxia-telangiectsia (Lai et al., 2004) and hemorrhagic symptoms (rescue of FV-VΙΙ) (Pinotti et al., 2006).
    
 	Aminoglycosides act on the proofreading mechanism of translation, by promoting a change in the 16S rRNA decoding centre from a tRNA binding conformation to a structure that increases the misincorporation of near-cognate amino acids. This is due to stabilisation of the near-cognate codon recognition complex and an increase in two conformations that restrict the rate of amino acid incorporation (Pape et al., 2000). The mechanism that the aminoglycosides use to create the read-through effect is not just determined by the presence of an mRNA stop codon alone, but also by an extended tetranucleotide termination signal. Successful read through of a stop codon was more common when cytosine follows the stop codon (Manuvakhova et al., 2000).

	This means that SMNΔ7 protein can now be expressed lacking exon 7 but with an additional nine amino acids of exon 8 (therefore altering the carboxy terminus). This read through property of the aminoglycosides is ideal, because as previously described the exon 1-6 construct with additionally attached amino acids to the carboxy terminus is sufficient to carry out cytoplasm localization. The effect of the read through properties of aminoglycosides leads to the formation of SMNΔ7 and an additional 9 amino acids, a fully stable and active protein.

	The aminoglycosides selected had different degrees of potency on the production of stable length SMN protein (Wolstencroft et al., 2005). Tobramycin (54) and amikacin (55) were both more effective at producing SMN compared to gentamicin (56). Gentamicin (56) has a similar structure to tobramycin (54) (Figure 1.17), as each molecule has three domains, of which the second is identical. 






Figure 1.17. Structures of the aminoglycosides tobramycin (54), amikacin (55) and gentamicin (56).






1.3.3 Biotransformation of Aminoglycosides

There are few examples of the derivatisation of aminoglycosides using biocatalytic tools. Much of the work undertaken on biocatalysis of aminoglycoside has been focused on the production of multivalent aminoglycosides, where more than one amine or hydroxyl group has been targeted for acylation. The production of multivalent aminoglycosides has been carried out in order to study their effect on DNA binding (Rege et al., 2004) and their anti-bacterial properties (Miura et al., 2003).






Figure 1.18. Scheme showing the biotransformation tert-butoxycarbonyl derivative of amikacin (57) with divinyl sebacate using B. subtilis protease (adapted from Miura et al., 2003).

Derivatisation of aminoglycosides using synthetic approaches, have yielded products with increased biological activity. An example of this is the synthesis of a multivalent vancomycin, which has shown greater anti-bacterial activity. This multivalent derivative is produced via a ring-opening metathesis polymerization technique and has led to an increase in anti-bacterial activity against vancomycin resistant Enterococci (VRE) (Arimoto et al., 1999). The multivalent amikacin's loss of activity is possibly due to a reduction in its permeability to the cell membrane and subsequent failure to bind to its target, rRNA. Vancomycin does not need to be permeable to the cell as it is active against the cell wall of VRE (Miura et al., 2003).



















The production of novel derivatives of natural products is important for the discovery of new compounds of medicinal interest. Natural products and their derivatives can be used as lead compounds in drug discovery. Therefore the aims of this project were to explore:

1) Synthesis of vinyl ester amino acids. 
Previous synthesis of vinyl ester amino acids has been limited to neutral and acidic amino acids. In the present work attempts will be made to synthesize basic amino acid vinyl esters; these are of particular interest in producing derivatives of natural product, which could potentially have increased binding affinity to nucleic acids.

2) Acylation of natural products.
Small-scale reactions will be carried out in order to identify the enzymes that produce the largest yields of natural product acylations with amino acid and commercially available (aliphatic and aromatic) vinyl acid esters. After identification of the most suitable enzymes for derivatisation, the reactions can be scaled up to isolate and characterise the products.

3) Screening synthesized derivatives for novel activity 








































Vinyl esters are the most commonly used substrates in non-aqueous lipase and protease biotransformations. Vinyl esters are often used as acyl donors, because the use of carboxylic acids in lipase and protease-catalysed esterifications leads to the release of water, as a by-product. The use of vinyl esters leads to the production of the non-nucleophilic by-product acetaldehyde (1) (via the tautomerization of vinyl alcohol (2), which is released after the collapse of the initial tetrhedral transition state). The production of acetaldehyde (1) and not the competing substrate water makes the reaction system almost completely irreversible. 

Synthesis of vinyl esters, of hydroxycarboxylic acids using palladium (II) acetate as a catalyst has previously been established (Lobell and Schneider, 1994). This method has also been used to synthesize amino acid vinyl esters, which were able to acylate various carbohydrates, in the presence of proteases (Boyer et al., 2001; Davis and Fairbanks, 2004).

In the present work, amino acid vinyl esters were synthesized, in order to study potential acylation by hydrolytic enzymes. The biotransformations of interest are the synthesis of amino acid acyl derivatives of the natural products naringin (43) and amikacin (55), a flavonoid and an aminoglycoside respectively.
  
Initial attempts were made to synthesize amino acid vinyl esters of the basic amino acids, arginine and lysine (61). The amino acid histidine was also studied, due to the lone pair of electrons of the nitrogen in the imidazole group, which has some basic properties. These amino acids are of particular interest, in attempting to acylate the carbohydrate groups of natural products. The addition of basic amino acids, may lead to greater interactions of aminoglycosides with nucleic acids such as RNA, as well as potentially increasing their biological activity. Derivatising flavonoids with basic amino acids may produce compounds with greater polarity and solubility in aqueous solutions, as well as enhancing their nucleic acid interactions.
            


















2.2.1.2 Palladium Catalysed Transvinylation Reaction












































2.3.2 Palladium Catalysed Transvinylation Reaction

	Smidt and Sabel (1960) made the initial attempts to synthesize vinyl esters by refluxing carboxylic acids with vinyl acetate (29) in the presence of the catalyst Li2PdCl4. This method proved to be largely unsuccessful, producing a negligible yield of product. The transvinylation of carboxylic acids was attempted with palladium (II) acetate as a catalyst, when refluxing with vinyl acetate (29) (Kawamoto et al., 1979). This proved to be a slightly more successful approach, but large numbers of by-products were also produced using this method.
	
The method selected for the synthesis of vinyl esters is that as described by Lobell and Schneider (1994), used for the transvinylation of hydroxycarboxylic acids with primary and secondary hydroxyl functions (e.g. 12-hydroxydodecanoic acid) and has since been applied to the synthesis of amino acid vinyl esters (Boyer et al., 2001; Davis and Fairbanks, 2004). For transvinylation reactions to proceed, they require the carboxylic acid and vinyl acetate (29) to be in the presence of the catalyst, palladium (II) acetate. The reactions are carried out under basic conditions, (with the addition of potassium hydroxide) at room temperature. The addition of potassium hydroxide prevents a side reaction occurring that results in the formation of acetals. The mechanism for the transvinylation reaction proceeds initially with the palladium (II) acetate complexing itself with vinyl acetate (29) (Figure 2.4). The palladium complex then dissolves due to anion exchange, as the acetate groups are substituted by the acidic species being vinylated (Kosak and Johnson, 1993). This leads to the formation of a palladium carboxylate complex. The palladium carboxylate complex is able to react with the double bond of vinyl acetate (29), forming a π-complex (Moiseev and Vargaftik, 2004). This complex is destroyed to release the amino acid vinyl ester product. 























Figure 2.5. Reaction scheme for the synthesis of N, N-di-tert-butoxycarbonyl-L-lysine vinyl ester (67).







2.3.2.1.2 Histidine and Arginine Derivatives 






Figure 2.6. Histidine derivatives selected for transvinylation


Employing the same methodology as that used for the synthesis of the lysine derivative (67), it was not possible to synthesize the vinyl ester of the di-tert-butoxycarbonyl histidine derivative (72). The reaction produced a large number of by-products, observed by TLC analysis. The large number of by-products made it not viable to isolate or identify the vinyl ester product. 






Figure 2.7. Nucleophilic attack of the imidazole tert-butoxycarbonyl protection group by a hydroxide ion.








Figure 2.8. Scheme showing anion exchange of acetate group of Pd(OAc)2 for the histidine derivative.







Figure 2.9. Arginine derivatives selected for transvinylation.


Both of these arginine derivatives (70 and 71), experienced similar problems to the Nα-tert-butoxylcarbonyl-N(im)-tosyl-L-histidine derivative (69). The solubility of the derivatives in vinyl acetate (29) was poor, which restricts their ability to anion exchange with the acetate groups complexed to the palladium catalyst. Negligible or no reactions were seen by TLC analysis after 24 hrs. 





Figure 2.10. The attempted synthesis of vinyl esters of histidine (72 and 73) and arginine (74 and 75). The above schemes were unsuccessful in yielding vinyl ester products.


An alternative approach to using basic amino acid vinyl esters is to use α-carboxy ester amino acids as acyl donors in non aqueous biotransformations. This approach has been carried out with N-protected α-carboxy esters of the basic amino acids arginine and histidine, in PPL-catalysed peptide synthesis (So et al., 1998). The use of α-carboxy ester amino acids as acyl donors in non-aqueous biotransformations has largely been used in peptide sythesis to date. Future work could be carried out to see if these acyl donors would be suitable for biotransformations of the natural products dealt with in this investigation. One problem associated with using these esters is that they produce an alcohol by-product (as the ester bond is cleaved in the formation of the acyl-enzyme intermediate). This can compete with the substrate molecule by nucleophilically attacking the acyl-enzyme intermediate.





2.3.2.2 Non-Polar Amino Acid Esters

	After failing to synthesize the vinyl esters of the basic amino acid dervatives (68-71), it was decided that we would try to synthesize vinyl esters of the amino acids phenylalanine (62) and valine (63). 

Vinyl esters of phenylalanine (62) have previously been synthesized (Boyer et al., 2001; Davis and Fairbanks, 2004) using the derivatives N-tert-butoxycarbonyl-L-phenylalanine (65), N-benzyloxycarbonyl-L-phenylalanine and N-acetyl-L-phenylalanine. These were synthesized to probe the vinyl esters ability to act as an acyl donor, but not towards the class of compounds that are being presently being studied; flavonoids and aminoglycosides. They have previously been screened for acylations of monosaccharides, such as mannose and galactose, as well as nucleotides (which contain ribose).
For the synthesis of the vinyl esters in the present work, the tert-butoxycarbonyl protected derivatives of phenylalanine (65) and valine (66) used. The previously described reaction used to synthesize the vinyl ester derivative of lysine (67) was applied to the synthesis of vinylated derivatives of phenylalanine (76) and valine (77) (Figure 2.11). The N-tert-butoxycarbonyl-L-phenylalanine vinyl ester (76) was synthesized in a 39% yield. The yield was lower than that previously recorded (Davis and Fairbanks, 2004). Large numbers of by-products were formed in this reaction, which made it difficult to separate the product from the reaction mixture, using flash chromatography over silica.

	 Using the same synthetic route as that described above, a yield of 62% was achieved for the N-tert-butoxycarbonyl-L-valine vinyl ester (77). Of all the amino acid vinyl esters mentioned in this chapter, the synthesis of the valine vinyl ester (77) was produced in the highest yield due to fewer by-products being formed in the reaction.
	





Figure 2.11. The synthetic route for the synthesis of the vinyl esters of N-tert-butoxycarbonyl-L-phenylalanine (76) and N-tert-butoxycarbonyl-L-valine (77).








































	The acylation of natural products using hydrolytic enzymes in non-aqueous reaction media has been an area of interest in recent years, due to their potential medicinal properties. Examples of natural products used for medicinal applications include paclitaxel (38) and penicillin. The synthesis of derivatives using a biocatalysis approach has been useful in changing the physical properties of flavonoids, by forming products that are more lipophilic, by the addition of fatty acids (Kontogianni et al., 2003). This approach increases the potential delivery of the flavonoid across the membrane and into the cell. The acylation of flavonoids using a biotransformation approach has led to the discovery of compounds with increased anti-microbial (Mellou et al., 2005) and antioxidant activity (Mellou et al., 2005; Katsoura et al., 2006) compared to the initial substrate. 
















3.2 Enzymatic Screening of Naringin Derivatisation
















 3.2.1.2 Enzymes 

Lyophilised enzymes supplied by Alphamerix (Cambridge, UK) were used as catalysts.The following enzymes were used for the screening of naringin acylation with the commercially available aromatic vinyl esters, aliphatic vinyl esters and succinic anhydride: Achromobacter spp. lipase (EC 3.1.1.3), Alcaligenes spp. lipase A1 (EC 3.1.1.3), Alcaligenes spp. lipase A2 (EC 3.1.1.3), Aspergillus spp. L-aminoacylase (3.5.1.14), Aspergillus melleus protease (EC 3.4), A. niger lipase (EC 3.1.1.3), Aspergillus oryzae protease (EC 3.4.23.6), B. lentus protease (EC 3.4.21.62), B. stearothermophilus protease (EC 3.4.24.8), B. subtilis protease (EC 3.4.21.62), Bromeliaceae spp. bromelain (EC 3.4.22.32), Can. antarctica lipase A (EC 3.1.1.3), CALB (EC 3.1.1.3), CALB (immobilised) (EC 3.1.1.3), Can. cylindracea lipase C1 (EC 3.1.1.3), Can. cylindracea lipase C2 (EC 3.1.1.3), Carica papaya papain (EC 3.4.22.2), Fiscus spp. ficin (EC3.4.22.3), Mucor miehei lipase (EC 3.1.1.3), Mucor javanicus lipase (EC 3.1.1.3), Penicillium camembertii lipase (EC 3.1.1.3), Pseudomonas cepacia lipase P1 (EC 3.1.1.3), P. cepacia lipase P2 (EC 3.1.1.3), Pseudomonas fluorescens lipase (EC 3.1.1.3), P. stutzeri lipase (EC 3.1.1.3), Rhizopus spp. lipase (EC 3.1.1.3), Rhizopus niveus lipase (EC 3.1.1.3),  R. niveus protease (EC 3.4.24), Rhizopus oryzae lipase (EC 3.1.1.3), R. oryzae protease (EC 3.1.1.3) and R. oryzae peptidase (EC 3.4.23.1).
	





Reactions were carried out in the solvent acetone.






For screening with amino acid vinyl esters, the following TLC stain solution was used to visualise compounds with amine groups: 1.5 g of ninhydrin (Acros Organics) was dissolved in 100 ml of butanol and then 3 ml of acetic acid was added. 		













3.2.2.1 Enzyme Screening for Acylations of Naringin

The screening for naringin esters was carried out in 1.5 ml vials. In each reaction 10 mg of lyophilised enzyme was added to the reaction mixture, which contained 25 mg (4.31 μmol) naringin and 5 M equivalent of vinyl ester (vinyl acetate, vinyl benzoate, vinyl butyrate, vinyl cinnamate, vinyl crotonate, N, N-di-tert-butoxycarbonyl-L-lysine vinyl ester, N-tert-butoxycarbonyl-L-phenylalanine vinyl ester and N-tert-butoxycarbonyl-L-valine vinyl ester) or succinic anhydride, dissolved in 1 ml acetone. The vials were sealed and then placed in a G25 shaker incubator (New Brunswick, New Jersey, USA) for 72 hrs, at 150 rpm, 28 ˚C.
       
After 72 hrs, the reaction mixtures were transferred to 1.5 ml plastic tubes (Eppendorf) and were centrifuged at 13,000 rpm for 5 mins. The supernatants were poured into 1.5 ml plastic tubes. 400 μl of acetone were added to the reaction pellets. These were vortexed to resuspend the pellet and were then centrifuged for a further 5 mins at 13,000 rpm in a Mini-Spin microfuge (Eppendorf). The second supernatant was then transferred to the new 1.5 ml plastic tubes as well. 

 	Control reactions were also run to compare the biotransformation reactions (they were also run for 72 hrs and had the same post-reaction treatment):

Control 1: 10 mg enzyme, 5 M equivalents of vinyl ester (or succinic anhydride) to theoretical moles of 25 mg naringin and 1 ml acetone.

Control 2: 25 mg (4.31 μmol) naringin, 5 M equivalents of vinyl ester (or succinic anhydride) and 1 ml acetone.

Control 3: 25 mg (4.31 μmol) naringin and 1 ml acetone.


TLC was used to make a qualitative analysis of the reaction mixtures. The following elution system was used to analyse the reaction mixtures: chloroform/methanol/water (4:1:0.3 v/v). Naringin and their esters were visualised under UV light (254 nm). The reaction mixtures were visualised with ninhydrin (amino acid vinyl esters) and potassium potassium permanganate (VII) (non- amino acid vinyl esters and succinic anhydride).

Reverse phase HPLC was conducted to carry out the analysis of the conversion of naringin to the esters, where TLC had identified a ‘hit’. The different compounds were separated using a gradient of acetonitrile and water (containing 0.1% acetic acid) at a flow rate of 1 ml/min at room temperature:

Elution method 1 (acyl donors: vinyl benzoate, vinyl butyrate, vinyl cinnamate and vinyl crotonate): A linear gradient from 10 to 60% acetonitile in water (16 mins), followed by 60% acetonitrile (2 mins). Linear gradient from 60 to 10% acetonitile (2 mins), followed by 10% acetonitrile (2 mins).

Elution method 2 (acyl donors: vinyl acetate and succinic anhydride): A linear gradient from 10 to 50% acetonitile in water (20 mins), followed by 50% acetonitrile (1 min). Linear gradient from 50 to 10% acetonitile in water (2 mins). 

Elution method 3 (acyl donors: N, N-di-tert-butoxycarbonyl-L-lysine vinyl ester, N-tert-butoxycarbonyl-L-phenylalanine vinyl ester and N-tert-butoxycarbonyl-L-valine vinyl ester): The gradient was preceded by 10% acetonitile (4 mins). A linear gradient from 10 to 60% acetonitile in water (10 mins), followed by 60% acetonitrile (9 mins). Linear gradient from 60 to 10% acetonitile (2 mins), followed by 10% acetonitrile (3 mins).









aP, area % product
aS, area % of naringin (standard)  


Figure 3.1. Formula used to calculate the levels of conversion of naringin with the acyl donors to form the respective ester derivative.


3.2.2.2 Protein Sequence Alignment

	The primary amino acid sequence of interest was input into BLAST (Altschul et al., 1997). Protein BLAST was performed to conduct a pair wise alignment of the query sequence to that of other sequences deposited in either protein or gene sequence databases. Sequence alignment of similar protein sequences was carried out using ClustalW (Thompson et al., 1994).


3.2.2.2 Protein Homology Modelling

If a protein sequence has over 35% sequence identity to another protein sequence whose structure is known, it is possible to produce a model of the unknown using the known structure. This is called homology modelling. This can be used to investigate the structural features of enzymes that carry out successful biotransformations.

 The homology modelling was carried out using the tools in the software package MOE ™ (Lin, 2005). The quality of the model was assessed by PROCHECK (Morris et al., 1992; Laskowski et al., 1993).  Protein structure were visualised using PyMOL (Delano, 2002).
	
































For the screening of naringin (43) with vinyl esters the temperature 28 °C was used. This was selected, as it is a mild temperature which many of the enzymes selected for screening are active at. Non-aqueous biotransformations have previously been carried out at a range of temperatures from –40 °C to 100 °C (Bornscheuer et al., 1992; Sakai et al., 1998).

Two factors had to be considered when selecting the solvent for the reaction media. Firstly the solvent had to be able to dissolve naringin (43). Secondly a balance has to be struck with the polarity of the solvent (a polar solvent will be required in order to dissolve the carbohydrate-flavane structure of naringin (43)) and the effect it will have on stripping essential water molecules, which are necessary for the enzyme to function (Gorman and Dordick, 1992; MacNaughtan et al., 1993). In this investigation it was decided to use the solvent acetone, which has previously been used for naringin (43) biotransformations (Kontogianni et al., 2001). This previous investigation showed larger conversion yields of naringin (43) in acetone compared to other polar solvents, such as dioxane and tert-butanol.





Enzyme	Naringin conversion with acyl donor (%)
	Vinyl acetate(29)	Vinyl benzoate(83)	Vinyl butyrate(24) 	Vinyl cinnamate(51)	Vinyl crotonate(80)	Boc-pheVinylester(76)
Lipase A1, Alcaligenes spp.	92	4	58	Noreaction	5	6
Lipase A2, Alcaligenes spp	88	4	36	14	Noreaction	19
Lipase, Achromobacter spp.	28	Noreaction	Noreaction	Noreaction	4	3
Lipase B, Can. antarctica	86	Noreaction	82	Noreaction	4	Noreaction
Lipase C2, Can. cylindracea	9	4	8	14	2	Noreaction
Lipase, M. miehei	13	No reaction	9	Noreaction	Noreaction	Noreaction
Lipase P1, P. capacia	14	Noreaction	10	Noreaction	Noreaction	Noreaction
Lipase, P. stutzeri	92	23	84	26	62	Noreaction











HPLCMethod	Retention times of naringin and acyl derivatives (mins)









3.4.1.2 Aliphatic Vinyl Esters
 
P. stutzeri lipase produced 92%, 84% and 62% conversion of naringin (43) when screening with the acyl donors vinyl acetate (29), vinyl butyrate (24) and vinyl crotonate (83) (Table 3.1). In previous work, the preferred enzyme for the acylation of flavonoids including naringin (43), with aliphatic vinyl esters has been CALB (Ishiharai et al., 2002; Passicos et al., 2004; Katsoura et al., 2006). The use of P. stutzeri lipase in biotransformations has previously been limited to secondary alcohol acylations, which are otherwise difficult to acylate with CALB due to steric hindrance (Magnusson et al., 2005). P. stutzeri lipase has been used to acylate α-hydroxyketones, containing phenyl groups (Martínez et al., 2004; Hoyos et al., 2008).

From the screening of naringin (43) with vinyl acetate (29), P. stutzeri lipase produced the largest conversion as measured by HPLC. It should also be noted that Alcaligenes spp. lipase A1 produced an equally large conversion of 92%. As well as the previously mentioned CALB, the Alcaligenes spp. lipase A2 also gave a large conversion of naringin (43) (86%). Three other enzymes were identified that gave smaller levels of conversion (less than 30%). 
From screening with vinyl butyrate (24), P. stutzeri lipase and CALB were the most effective in producing the largest conversions of naringin (43) (higher than 80% conversion) (Table 3.1). Achromobacter spp. lipase A1 and A2 also carried out significant conversions of naringin (43), 58% and 36% yields respectively. The synthesis of a naringin butyrate ester (53) has previously been described using CALB (Katsoura et al., 2006; 2007). In these investigations CALB was used to catalyse the naringin butyrate ester (53) in a range of solvents including ionic liquids and the organic solvent acetone. At 50 °C in acetone, a 99% conversion yield of naringin (43) has been measured over 72 hrs (yields were less than 65% when ionic liquids were used). This is higher than the conversion yield given by P. stutzeri lipase and CALB during our investigation, which means CALB, was more active at the higher temperature for this biotransformation. In the previous investigations by Katsoura et al., (2006; 2007) the enzyme CALB was shown to be regioselective for naringin’s (43) primary hydroxyl, 6’’-OH. 

From screening naringin (43) with vinyl crotonate (80) only P. stutzeri lipase showed a reasonable conversion yield by HPLC analysis (62%). Four other lipases gave smaller levels of conversion (less than 10%), including CALB (Table 3.1). 

	It should be noted that for all enzymes screened for the acylation of naringin (43) with aliphatic vinyl esters, only the lipases produced derivatives. Many of the enzymes screened did not acylate naringin (43), which could be caused by factors that include the water-stripping effect of acetone (Gorman and Dordick, 1992; MacNaughtan et al., 1993) and enzyme selectivity for the substrates.






3.4.1.3 Aromatic Vinyl Esters

P. stutzeri has not previously been used to synthesize derivatives of naringin (43) with aromatic vinyl esters. From screening for acylations of naringin (43) with vinyl benzoate (83), P. stutzeri lipase gave a modest conversion yield of 23% (Table 3.1). Three other enzymes carried derivatives of naringin (43), but HPLC recorded conversion levels of less than 5% for each. 

From the screening of naringin (43) with vinyl cinnamate (51), only P. stutzeri lipase gave a reasonable conversion yield (26%) (Table 3.1). The enzymes Can. cylindracea lipase C2 and Alcaligenes spp. lipase A2 gave a low yield of naringin (43) conversion when screened with vinyl benzoate (83) (less than 15%).

CALB was unsuitable for catalysing the acylation of naringin (43) with either of the aromatic vinyl acid esters (51 and 83), using these reaction conditions. The synthesis of a naringin cinnamate derivative has previously been carried out using CALB and vinyl cinnamate (51) (Ishiharai et al., 2002).  The synthesis was carried out over 336 hrs at 37 °C, with dry acetone as the solvent. Ishiharai et al., (2002) measured a 64% conversion yield of naringin (43) under these conditions. From our screening results, conversion of naringin (43) was achieved using P. stutzeri lipase in a much smaller period of time, at a milder temperature. CALB was unable catalyse the conversion of naringin (43) under the conditions employed during our investigation. In the previous study by Ishiharai et al., (2002) the enzyme CALB was shown to be regioselective for naringin’s (43) primary hydroxyl, 6’’-OH.










Figure 3.3. HPLC chromatograph showing multi-product formation catalysed by P. stutzeri lipase, when using succinic anhydride as an acyl donor.


Previous use of this acyl donor in biotransformations has been used to acylate compounds, which only have one secondary hydroxyl group (Bouzemi et al., 2004; Bogel et al., 2008), unlike naringin (43) and other carbohydrates, which are polyhydroxylated.





Figure 3.4. HPLC chromatograph showing the control reaction for naringin (43) and succinic anhydride (control 2).






3.4.1.5 Amino Acid Vinyl Esters


3.4.1.5.1 N-tert-Butoxycarbonyl-L-Phenylalanine Vinyl Ester

	From the screening of enzymes for the acylation of naringin (43) with N-tert-butoxycarbonyl-L-phenylalanine vinyl ester (76), Alcaligenes spp. lipase A2 gave a 19% conversion yield (Table 3.1).  Lipases from Alcaligenes spp. have had limited applications in biocatalysis. There are very few examples where Alcaligenes spp. lipases are used as an alternative to other classical lipases in non-aqueous biocatalysis. They have been shown to be active in lipase-catalysed enantioselective transesterification of cyanohydrin with vinyl acetate (29), in non-aqueous reaction media (Zhang et al., 2002; 2004). Another example is in the asymmetric desymmetrisation of a 1,3-propanediol. Despite being employed in this biotransformation, other lipases showed higher levels of enantiomeric resolution of the substrate (Takabe et al., 2003).
	
Another Alcaligenes spp. enzyme, the A1 lipase, showed a lower level of conversion of naringin (43). Achromobacter spp. lipase also gave a small conversion yield by HPLC analysis (Table 3.1).





3.4.1.5.2 N-tert-Butoxycarbonyl-L-Valine and N, N-di-tert-Butoxycarbonyl-L-Lysine Vinyl Esters










3.4.2 Synthesis of Naringin Derivatives





3.4.2.1 Aliphatic Vinyl Esters






Figure 3.6. Reaction scheme showing the biotransformation of naringin (43) with the aliphatic vinyl acid esters (24, 29 and 80). P .stutzeri lipase carries out a regioselective acylation of the primary hydroxyl group of naringin (43) to produce naringin-6’’-O-acetate (81), naringin-6’’-O-butyrate (53) and naringin-6’’-O-crotonate (82).






3.4.2.2 Aromatic Vinyl Esters










3.4.2.3 N-tert-Butoxycarbonyl-L-Phenylalanine Vinyl Ester

	After identifying an enzyme-catalysed reaction between naringin (43) and the N-tert-butoxycarbonyl-L-phenylalanine vinyl ester (76) on a small-scale, it was decided to scale up the reaction with Alcaligenes spp. lipase A2. Despite conversion of naringin (43) measured by HPLC (Figure 3.8), the reaction did not carry out the expected esterification to produce the naringin ester derivative (86) (Figure 3.9). 












Figure 3.9. Scheme showing the attempted synthesis of the N-tert-butoxycarbonyl-L-phenylalanine naringin-ester (86). The reaction catalysed with Alcaligenes spp. lipase A2 was unable to acylate naringin (43) with the N-tert-butoxycarbonyl-L-phenylalanine vinyl ester (76).

None of these clusters fit the expected profile for N-tert-butoxycarbonyl-L-phenylalanine naringin ester (86). The required mass for this ester product would be a molecular weight of 827. The corresponding molecular masses of molecules producing these clusters would be 209, 265, 530, 795 and 1050 respectively. As TLC and HPLC identified a reaction product, the N-tert-butoxycarbonyl-L-phenylalanine naringin ester (86) could have been formed in a lipase-catalysed reaction, but was unstable (due to an unknown mechanism). Alternatively, a side reaction may have occurred in the presence of the lipase. Cluster 2 corresponds to N-tert-butoxycarbonyl-L-phenylalanine (65) the product of N-tert-butoxycarbonyl-L-phenylalanine vinyl ester (76) hydrolysis.






Figure. 3.10. +NanoESI spectra showing the reaction products from the attempted acylation of naringin (43) with the N-tert-butoxycarbonyl-L-phenylalanine vinyl ester (76). The molecular ion clusters identified in the spectra do not correspond to the predicted molecular weight of the acylated product (86).


3.4.3 Regioselectivity of P. stutzeri Lipase

	The regioselectivity of P. stutzeri lipase in non-aqueous reaction conditions was determined by the use of NMR. From the 13C NMR, a change in chemical shift (ppm) for the 6’’-CH2-, carbon atom, of the glucose ring was seen for each derivative (Table 3.3). The CH2 group of the glucose ring is bonded to the primary hydroxyl group (6’’-OH), which has been the target for lipase acylations of naringin (43) in previous investigations (Kontogianni et al., 2001; 2003; Ishiharai et al., 2002; Gayot et al., 2003; Passicos et al., 2004; Katsoura et al., 2006; 2007). This is a common feature of many non-aqueous biotransformations of polyhydroxylated substrates (Hennen et al., 1988; Danieli et al., 1995; 1997; Nakajima et al., 1999; Fan et al., 2004). 
	









Table 3.3. Table showing the 13C chemical shift (ppm) for 6’’-CH2-OH of naringin (43) and its lipase-catalysed derivatives. 






3.4.4 P. stutzeri Lipase Structure

	To identify the catalytic residues of P. stutzeri lipase, sequence alignment was carried out to compare its primary structure with lipases with similar sequences. The sequences of similar lipases were obtained from a protein BLAST search (Figure 3.11).  The amino acid sequence for P. stutzeri lipase has been obtained from genomic sequencing investigations (Yan et al., 2008) and the protein remains unstudied. In the alignment studies, the amino acid sequence of P. stutzeri lipase was compared to three other lipases (identified by the protein BLAST search):  P. mendonica lipase (82% sequence identity) (Bott and Wu, 2007), Str. griseus lipase (38% sequence identity) (Ohnishi et al., 2008) and Geobacillus spp. lipase (33% sequence identity) (Lucas et al., 2008). 






Figure 3.11. Amino acid sequence of alignment of P. stutzeri lipase (NCBI accession number: YP_001174476), P. mendonica lipase (2FX5_A), Str. griseus lipase (YP_001823515) and Geobacillus spp. lipase (ZP_03040339). Amino acid residues across the lipases that are conserved are shaded in black boxes. Aligned residues of the lipases, which have similar properties, are shaded in grey boxes. The alignment was created using ClustalW (Thompson et al., 1994). Red asterisks indicate the catalytic triad residues of P. stutzeri lipase.







Figure 3.12. Modelled structure of the active site of P. stutzeri lipase, showing the active site residues of the catalytic triad: Ser149, His229 and Asp199. This figure was generated using the program PyMOL (DeLano, 2002).


















Figure 3.14. a) The electrostatic surface potential calculated for the P. stutzeri lipase model. Positively charged residues are shown in blue and negatively charged residues are shown in red. b) The active site residues are shown in the cavity: Serine (red), histidine (blue) and aspartic acid (green). This figure was generated using the program PyMOL (DeLano, 2002).



















































	Flavonoids are secondary metabolites of plants, which display antioxidant activity. This makes them biologically useful compounds, reducing species that can carry out oxidative attacks on LDL and lipids. The intake of flavonoids in the diet has led to the consumption of red wine being viewed as beneficial to an individual’s health (Gronkbaek et al., 1995). The antioxidant activity of red wine is attributed to a range of flavonoids, which include quercetin (47), myricetin and kaempferol (McDonald et al., 1998; Tsanova-Savova and Riharova, 2002). Another source of flavonoids in the diet are those that are acquired from tea infusions, which have previously demonstrated an ability to reduce the levels of LDL oxidation (Kasaoka et al., 2002). The main two classes of flavonoids found in green tea are the flavanols (e.g. catechins) and flavonols (e.g. kaempferol) (Wang et al., 2000). 

In the present study, the antioxidant activity of the flavonoid naringin (43) from grapefruit is being compared directly to the derivatives (53, 81, 82, 84 and 85) that have been synthesized by lipase-catalysed esterifications (see section 3.4.2). In previous work, regioselective acylations of flavonoids have produced derivatives which have greater lipophilicity and antioxidant activity, compared to the original flavonoid (Mellou et al., 2005; Katsoura et al., 2006). It has previously been shown that protective species, against LDL oxidation, including chemically derivatised isoflavones, have shown increased antioxidant activity when they have been modified to become more lipophilic (Meng et al., 1999). Chalas et al., 2001 J. Chalas, C. Claise, M. Edeas, C. Messaoudi, L. Vergnes, A. Abella and A. Lindenbaun, Effect of ethyl esterification of phenolics on low-density lipoprotein oxidation, Biomed. Pharmacother. 55 (2001), pp. 54–60. Article | PDF (48 K) | View Record in Scopus | Cited By in Scopus (28)It has also been shown that the esterification of some phenolic acids enhances protective activity against copper-catalysed peroxidation of LDL (Chalas et al., 2001).

	Many methods of testing antioxidant activity of small molecules, proteins and enzyme systems are presently known. There are two main types of assay that can be used to measure the antioxidant effects of molecules; these are based on either hydrogen atom transfer or single electron transfer. For the comparative study of naringin (43) and their derivatives (53, 81, 82, 84 and 85) antioxidant properties, it was decided to use a single electron transfer assay, the Trolox Equivalence Antioxidant Capacity (TEAC) assay. This assay measures the reduction of Cu2+ to the Cu+ ion, carried out by the antioxidant sample. 






	The screening of the antioxidant activity of naringin and the synthesized derivatives was carried out with a TEAC assay kit (Biovision, California, USA). The derivatives were screened according to the manufacturer’s instructions (see section 4.2.2). The kit consisted of Cu2+ reagent, assay diluent, protein mask solution and trolox standard. 

Acros Organics supplied naringin and the synthesis of the derivatives has previously been described (see section 3.4.2).

The solvent DMSO (Fisher) was used to dissolve samples.

1.5 ml plastic tubes were supplied by Eppendorf. 















	Solutions of 100 mM of naringin and their derivatives (antioxidants) were made up by dissolving them in 500 μl of DMSO. This was diluted with DMSO (1/9 v/v) to form a 10 mM solution. 10 μl of these solutions were transferred to individual wells, to give 10 nmol of antioxidant per well. To each antioxidant sample well, 10 μl of protein mask solution and 80 μl of ddH2O were added.


4.2.2.3 Total Antioxidant Capacity Assay
	
	To the trolox standard solutions and the antioxidant samples, 100 μl of Cu2+ working solution (Cu2+ reagent diluted with assay diluent: 1/49, v/v) was added to each well. The wells were left to incubate at room temperature for 1.5 hrs. The assay mixtures were diluted with ddH2O, so the absorbances for each sample fell within the 0-20 nmol trolox standard range. The absorbances of these wells were measured at 570 nm. The antioxidant capacity of each sample was calculated using the formula in figure 4.1 (from manafacturer’s notes).


Sample antioxidant capacity =           ((Sample absorbance -blank absorbance) 
                                                                    X (μl of sample))
                                                                (Gradient of trolox standard curve)







4.3 Results and Discussion






Figure 4.2. Diagram showing naringin (43) chelating Cu2+ .


The other proposed mechanism in which flavonoids like naringin (43) act as antioxidants, is through free radical scavenging activity. This is carried out through the free hydroxyl groups of the A, B and C rings of the flavane structure, which donate hydrogen to oxidative species (Amic et al., 2003). Figure 4.3 shows the B-ring of the flavane structure of naringin (43). The hydroxyl group found at the C’4-position of this ring (4’-OH) is responsible for the free-radical scavenging activity of the naringin (43) molecule (Arora et al., 1998).

Naringin (43) lacks some of the flavane core structural features, which contribute to a flavonoids ability to scavenge free radicals. Many other flavonoids contain a 3’, 4’- di-OH system of the B-ring. Other flavonoid structural features include an unsaturated bond between C2 and C3 of the C-ring, with a hydroxyl group substituent at C3. Activity can also be attributed to a 7, 8- di-OH substituton of the A ring. Without these, naringin’s  (43) free radical scavenging  is isolated to the  4’-OH  of

Figure 4.3. Diagram showing the free radical scavenging activity of the 4’-OH B-ring of the flavonoid naringin (43).







Figure 4.4. Structure of naringin (43) flavane compared to a flavane structure, which has been shown to provide maximum antioxidant activity.


The assay selected for screening naringin (43) and its derivatives (53, 81, 82, 84 and 85), investigates the ability of these compounds to reduce Cu2+ to Cu+. The Cu+ coordinates itself to a naringin (43) (which has lost a hydrogen atom, to form a chelated species with a reduced charge of +1, Figure 4.2) (Pereira et al., 2007). 

The assay used to measure the antioxidant activity is the TEAC assay (Re et al., 1999), which is based on electron transfer:  

Oxidant + e- (from antioxidant sample) → Reduced oxidant + Oxidized sample

The TEAC assay uses trolox as a standard antioxidant. The assay kit used, measures the ability of the samples to reduce the species Cu2+, as a function of the trolox standard (see appendix 3 for trolox standard curve):

ROH (naringin and derivatives) + Cu2+ → [ROCu]+ + H+
(The Cu+ chelates a colorimetric probe; absorbance was measured at 570nm).

It is proposed that naringin (43) may have multiple mechanisms of antioxidant activity, but in the present study the ability to reduce Cu2+ is being investigated. This study does not account for the free radical scavenging of the B-ring 4’-OH. Copper chelating is the main system in which the antioxidant activity of a flavonoid like naringin (43) is accounted for (preventing LDL-copper induced peroxidation). 

	Our results showed that two derivatives had a higher total antioxidant capacity than the flavonoid naringin (43). These were naringin-6’’-O-acetate (81) and naringin-6’’-O-crotonate (82). Our results also showed that derivatisation of naringin (43) with the aromatic vinyl esters (51 and 83) led to a large reduction in the total antioxidant capacity (Figure 4.5). The exact mechanisms by which two of these acyl derivatives have increased copper reducing properties are still not clear, so further work to understand these mechanisms is important. The antioxidant activity of the naringin derivatives (53, 81, 82, 84 and 85) could have been determined by numerous factors, some of which are discussed below.





Figure 4.5. Graph comparing the relative total antioxidant capacity of naringin (43) and its derivatives (53, 81, 82, 84 and 85). Error bars show the standard errors for each sample. Assays were carried out in duplicate. For exact values see appendix 4.


The electron-donating or -withdrawing properties of the acyl groups may alter total antioxidant capcity of the derivatives. This could explain the lower total antioxidant capacities of naringin-6’’-O-benzoate (84) and naringin-6’’-O-cinnamate (85). The addition of an aromatic ring to naringin may have an electron withdrawing effect. This could lead to a reduction in the derivatives ability to donate electrons to oxidative species, in this case Cu2+ (Laranjinha et al., 1996). 

Steric hindrance and the inductive effect may help to explain why naringin-6’’-O-acetate (81) provided the highest total antioxidant capacity. The acetate derivative (81) is able to donate electrons and is smaller than the other acyl donors, so it does not sterically hinder the chelation of Cu2+. The balance of these two properties may determine the strength of the derivatives antioxidance.

It has been proposed that the presence of an unsaturated bond in the acyl derivative could potentially increase the antioxidant activity of a flavonoid derivative, but the mechanism is unknown. This effect has been demonstrated by a direct comparison of acyl derivatives of rutin (48) with the same chain lengths, synthesized with vinyl stearate (C18:0) and oleic acid (C18:1). The oleic derivative showed a greater antioxidant effect on LDL and serum copper-induced oxidations, compared to the stearate derivative (Katsoura et al., 2006). Similarly, in our investigation naringin-6’’-O-crotonate (82) was a stronger antioxidant, compared to naringin-6’’-O-butyrate (53). 

It has also been proposed that the enzyme regioselectivity for flavonoids may affect the antioxidant properties (Mellou et al., 2005). This theory at present remains unexplored. As all derivatives (53, 81, 82, 84 and 85) are regioselectively identical, this factor will not determine the difference in antioxidant activity in the present investigation.

The total antioxidant capacity values of antioxidants in apples have been determined previously (Lee et al., 2003). The flavonoid quercetin (47) recorded a total antioxidant capacity value of 3.06, which lies in a similar range to that of naringin-6’’-O-acetate (81) (3.01) and naringin-6’’-O-crotonate (82) (2.86). These two derivatives had higher total antioxidant capacity values compared too two other flavanoids identified in apples- epicatechin (2.67) and procyanidin B2 (2.36). Naringin (43) and all the derivatives (53, 81, 82, 84 and 85) had higher total antioxidant capacity values compared to vitamin C (1.00), which has both antioxidant and pro-oxidant activity (Satohand and Sakagami, 1997; McGregor and Biesalski, 2006). The total antioxidant capacity values of other biologically important antioxidants including bilirubin (1.50), uric acid (1.00) (Miller, 1998) and vitamin E (1.00) (Pietta et al., 2000) have also been determined and are low in comparison to naringin (43) and the derivatives (53, 81, 82, 84 and 85). Naringin (43) and all the derivatives (53, 81, 82, 84 and 85) have a lower total antioxidant capacity value than that reported for the main antioxidant found in tea, epigallocatechin gallate (4.81) (Pietta et al., 2000). The high total antioxidant capacity of naringin-6’’-O-acetate (81) and naringin-6’’-O-crotonate (82) means that they could have potential biological applications, if they can be delivered to human tissue.

The TEAC assay is a useful assay to employ, since copper-induced oxidations are responsible for oxidative attack of LDL in biological systems. This assay demonstrates the effect naringin (43) and the derivatives (53, 81, 82, 84 and 85) have on the reduction of copper. In biological systems the presence of Cu2+ leads to LDL peroxidation. It is proposed that Cu2+ does not directly carry out the peroxidation of the LDL, but is initiated by antioxidants within the LDL structure (Abuja et al., 1997). An example of an antioxidant within the LDL structure that reduces Cu2+ is tocopherol. The reduction of Cu2+ by this antioxidant results in the formation of a radical species, which in turn oxidizes the LDL. Naringin (43) has also been implicated at the molecular level in other biological antioxidant systems, including increasing the activity of the enzymes SOD and catalase (Jung et al., 2003).






































Aminoglycosides have numerous biological properties; the most common, is their anti-microbial activity. In recent years, the rise in cases of antibiotic resistant strains of bacteria has lead to fatalities, e.g. methicillin-resistant Sta. aureus (MRSA) and Pseudomonas aeruginosa. This has led to an increase in the search for new antibiotic derivatives with anti-bacterial activity towards resistant strains (Yoshida et al., 2002). This makes amioglycosides ideal targets for derivatisation, to create libraries of biologically active molecules.

In this study the derivatisation of the aminoglycoside (antibiotic) amikacin (55) was studied, due to its potential treatment of the neuronal condition SMA (Wolstencroft et al., 2005). Attempts were made to acylate tetra-N-tert-butoxycarbonyl protected amikacin (57), with the amino acid vinyl esters (67, 76 and 77), using a biotransformation approach. Due to the high polarity of this compound, it was decided that the best approach for acylation was to carry out the biotransformations in a suitably polar solvent, such as DMF. The use of lipases in this solvent are restricted due to DMF’s water stripping effect (Gorman and Dordick, 1992; MacNaughtan et al., 1993). Protease-catalysed acylations were studied, due to their higher activity in the solvent DMF (Shibatani et al., 1997; Kitagawa et al., 1999). Proteases were also selected due to their previous success in acylating tert-butoxycarbonyl protected amikacin (57) (Miura et al., 2003) and their ability to acylate carbohydrates with amino acid derivatives (Boyer et al., 2001; Davis and Fairbanks, 2004). Protease-catalysed biotransformations can be enhanced in the presence of triethylamine, so this approach was also investigated, to examine the effect of reaction media on the acylation of amikacin (55) (Kise et al., 1988; Clapés et al., 1990).

The aim of the work was to synthesize two different types of derivatives. The first approach was the addition of the basic amino acid lysine (61). The addition of this amino acid was seen as an important derivatisation due to its basic nature, which could enhance interactions with the phosphate group of RNA. This approach is being investigated due to the increased binding affinities of aminoglycosides to RNA, when they have been chemically conjugated to the basic amino acid arginine (Litovchick et al., 1999).

As lysine (61) was the only basic amino acid vinyl ester (67) that was synthesized successfully, it was decided to study derivatisation by non-polar amino acid vinyl esters (76 and 77). These could potentially form derivatives that would have greater lipophilic characteristics than the initial aminoglycoside, making them more permeable to the cell membrane. As amikacin (55) is a highly polar molecule, even the uncharged species remains largely lipid insoluble (Rang et al., 1999).













































5.3 Enzymatic Screening of Amikacin Derivatisation





















Reactions  were carried  out  in the  solvent DMF.  For the  reactions carried  out 
with phosphate buffer, a buffer of 100 mM pH 8.0 was made by dissolving 1.25 g of dipotassium phosphate and 47 mg of potassium dihydrogen phosphate, in 50 ml of water. The buffer was filtered through a 0.2 μ filter (Whatman, Chalfont St Giles, UK). These aqueous biotransformations were carried out in the presence of triethylamine (Acros Organics).   













5.3.2.1 Non-Aqueous Protease-catalysed Reactions

The screening for tetra-N-tert-butoxcarbonyl amikacin esters was carried out in 1.5 ml vials. In each reaction 10 mg of enzyme was added to the reaction mixture, which contained 25 mg (25.4 μmol) tetra-N-tert-butoxcarbonyl amikacin and 5 M equivalent of vinyl ester (N, N-di-tert-butoxycarbonyl-L-lysine vinyl ester, N-tert-butoxycarbonyl-L-phenylalanine vinyl ester and N-tert-butoxycarbonyl-L-valine vinyl ester) dissolved in 1 ml of DMF. The vials were sealed and then placed in a G25 shaker incubator (New Brunswick) for 120 hrs, at 150 rpm, 40 °C. After 24 and 48 hrs, an additional 10 mg of enzyme was added respectively to the reaction mixtures.

After 120 hrs the reaction mixtures were transferred to 1.5 ml plastic tubes and were centrifuged at 13,000 rpm for 5 mins. The supernatants were poured into 1.5 ml plastic tubes. 400 μl of DMF was added to the reaction pellets. These were vortexed to resuspend the pellet and then centrifuged for a further 5 mins at 13,000 rpm in a Mini-Spin microfuge (Eppendorf). The second supernatants were then transferred to the new 1.5 ml plastic tubes as well. 

Control reactions were also carried out to compare with the biotransformation reactions (they were also run for 120 hrs and had the same post-reaction treatment):

Control 1: 3 X 10 mg enzyme (0, 24 and 48 hrs), 5 M equivalents of amino acid vinyl ester to theoretical moles of 25 mg tetra-N-tert-butoxcarbonyl amikacin and 1 ml DMF.

Control 2: 25 mg (25.4 μmol) tetra-N-tert-butoxcarbonyl amikacin, 5 M equivalents of amino acid vinyl ester and 1 ml DMF.

Control 3: 25 mg (25.4 μmol) tetra-N-tert-butoxcarbonyl amikacin and 1 ml DMF.





5.3.2.2 Aqueous Protease-catalysed Reactions

The screening for tetra-N-tert-butoxcarbonyl amikacin esters was carried out in 1.5 ml vials. In each reaction 10 mg of enzyme was added to the reaction mixture, which contained 25 mg (25.4 μmol) of tetra-N-tert-butoxcarbonyl amikacin and 5 M equivalent of vinyl ester (N, N-di-tert-butoxycarbonyl-L-lysine vinyl ester, N-tert-butoxycarbonyl-L-phenylalanine vinyl ester and N-tert-butoxycarbonyl-L-valine vinyl ester) dissolved in 976.5 μl DMF, 20 μl of 100 mM phosphate buffer pH 8.0 and 3.5 μl (25.4 μmol) triethylamine. The vials were sealed and then placed in a G25 shaker incubator (New Brunswick) for 120 hrs, at 150 rpm, 40 °C. After 24 and 48 hrs, an additional 10 mg of enzyme was added respectively to the reaction mixture. 

Control reactions were also run to compare the biotransformation reactions (they were also run for 120 hrs and had the same post-reaction treatment):

Control 1: 3 X 10 mg enzyme (0, 24 and 48 hrs), 5 M equivalents amino acid vinyl ester to theoretical moles of 25 mg (25.4 μmol) tetra-N-tert-butoxcarbonyl amikacin, 976.5 μl DMF, 20 μl 100 mM phosphate buffer pH 8.0 and 3.5 μl (25.4 μmol) triethylamine.

Control 2: 25 mg (25.4 μmol) tetra-N-tert-butoxycarbonyl amikacin, 5 M equivalents amino acid vinyl ester, 976.5 μl DMF, 20 μl 100 mM phosphate buffer pH 8.0 and 3.5 μl (25.4 μmol) triethylamine.

Control 3: 25 mg (25.4 μmol) tetra-N-tert-butoxycarbonyl amikacin, 976.5 μl DMF, 20 μl 100 mM phosphate buffer pH 8.0 and 3.5 μl (25.4 μmol) triethylamine.






























Figure 5.2. Reaction mechanism for the amino protection of amikacin (55) using di-tert-butoxycarbonate to yield tetra-N-tert-butoxycarbonyl amikacin (57) with release of carbon dioxide and butanol.


This method yielded 60%, which was lower than that recorded for the synthesis of penta-N-tert-butoxycarbonyl kanamycin, using this method. The yield compared to the synthesis of tetra-N-tert-butoxycarbonyl amikacin (57) by Miura et al., (2003), who yielded 61% under basic reaction conditions.


5.4.2 Biotransformation Screening 


5.4.2.1 Non-Aqueous Protease Biotransformation

From the proteases screened, none were able to carry out a successful acylation of tetra-N-tert-butoxycarbonyl amikacin (57). The proteases from B. lentus, B. stearothermophilus and B. subtilis failed to convert the substrate tetra-N-tert-butoxycarbonyl amikacin (57) into the respective amino acid ester derivatives (87-89). 
         
B. lentus protease was selected due to its application in previous biotransformations. It has previously been shown to be a robust enzyme, capable of carrying out enzymatic acylation reactions between vinyl esters and different alcohols in good yields (Lloyd et al., 1998). Initial efforts to use this enzyme to catalyse reactions with amino acid acyl donors have had mixed results. It has low affinity for the amino acid esters of the residues aspartate and glutamate, due to steric hindrance in the catalytic site (Khumtaveeporn et al., 1999). The double approach of mutagenesis and chemical modification can be used to reduce these restrictions of the wild type enzyme. The introduction of a cysteine for a methionine residue in the active site and chemical modification by a methanethiosulphanate reagent, increased B. lentus protease’s affinity to amino acid acyl donors that were charged, or had branched side chains. The mutant B. lentus protease was able use amino acid acyl donors as substrates in biotransformations, which the wild type enzyme was unable to use. This indicates that B. lentus protease is limited by its affinity to certain acyl donor. 

B. lentus protease has been used for the construction of pyranoside-peptide conjugates, using amino acid vinyl esters as acyl donors (Boyer et al., 2001; Davis and Fairbanks, 2004). In these investigations N-tert-butoxycarbonyl-L-phenylalanine vinyl ester (76) was used as an acyl substrate. We were not able to use B. lentus protease to synthesize the phenylalanine ester (88) of tetra-N-tert-butoxycarbonyl amikacin in our investigation. Lysine (87) and valine (89) esters could also not be produced. This could be the result of steric hindrance, which has previously been problematic when attempting biotransformations with acidic amino acid derivatives (Khumtaveeporn et al., 1999). Another factor, which could limit the activity of the enzyme, (especially in the case of phenylalanine) is the water stripping effect of the polar solvent DMF (see below).

B. subtilis protease was also studied, as it has been shown to be active in numerous organic solvents (e.g. pyridine and DMF) (Riva et al., 1988). B. subtilis protease was also of interest because it has has had some, but limited success, in the acylation of the substrate tetra-N-tert-butoxycarbonyl amikacin (57) (Miura et al., 2003). No conversion of tetra-N-tert-butoxycarbonyl amikacin (57) was detected when using B. subtilis protease, which could have been due to the effect of the solvent DMF. Despite reports of protease activity in this solvent, it is highly polar and has the ability to strip functional waters that are essential to maintaining the tertiary structure of enzymes (Gorman and Dordick, 1992; MacNaughtan et al., 1993).  





5.4.2.2 Aqueous Protease Biotransformation

The synthesis of tetra-N-tert-butoxycarbonyl amikacin amino acid esters (87-89) was also unsuccessful when introducing a buffer solution (containing triethylamine) into the reaction media. The introduction of triethylamine can increase protease activity and neutralise acids formed by the hydroysis of vinyl acid esters (Kise et al., 1988; Yamamoto and Kise, 1993).The addition of water to the reaction media did not lead to the formation of amikacin amino acid esters (87-89), so the water stripping effect of DMF is less likely to be a restricting variable in the non-aqueous reactions. 








































































































































In a 1000 ml round-bottom flask N-tert-butoxylcarbonyl-L-valine (10 g, 46 mmol) was dissolved in vinyl acetate (100 eq., 428 ml, 4.6 mol). Palladium (II) acetate (0.2 eq., 2.11 g, 9.2 mmol) and potassium hydroxide (0.1 eq., 258 mg, 4.6 mmol) were added and the solution was stirred at room temperature, under nitrogen for 24 hrs. The reaction mixture was added to diethyl ether (1.5 L) and filtered through celite. The crude product was concentrated in vacuo and purified by flash chromatography (hexane/ethyl acetate 13/2 v/v) to yield a colourless oil (8.32 g, 62%, over two columns); (Found: C, 59.51%; H, 8.92%; N, 5.74%, calc. for C12H21NO4, requires C, 59.24%; H, 8.70%; N, 5.76%); (Found MNa+ 266.1360. C12H21NO4Na requires 266.1368); [α]D29= –26.0 (c, 0.01, in ethanol);  νmax (NaCl cm-1) 3367, 3093, 2970, 2871, 1758, 1715, 1647 and 1504; δH (300 MHz: CDCl3: Me4Si) 7.13 (dd, J 7.0 Hz, J 13.0 Hz, 1H, CH=CH2), 4.93 (br d, J 9.0 Hz, 1H, NH), 4.82 (dd, J  1.5 Hz, J 13.0 Hz, 1H, CH=CHH), 4.51 (dd, J 1.5 Hz, J  7.0 Hz, 1H, CH=CHH), 4.20-4.11 (m, 1H, CH),  2.14-1.95 (m, 1H, CH), 1.32 (s, 9H, CH3) and 0.87-0.78 (m, 6H, CH3); δC (75 MHz: CDCl3: Me4Si) 170.12 (C), 156.00 (C), 141.23 (CH), 99.08 (CH2), 80.32 (C), 58.76 (CH), 31.46 (CH), 28.66 (CH3), 19.37 (CH3) and 17.90 (CH3); m/z (+NanoESI) 266 (MNa+, 100%), 261 (MNH4+, 63), 244 (MH+, 74), 188 (24) and 144 (14). 
















































































































































































































In this work a range of lipases and proteases were screened for their ability to acylate natural compounds, which have (potential) applications in biomedicinal processes. The ester derivatives synthesized using biotransformations in this investigation were screened for their potential use as medicinal compounds. 

A range of acyl donors were used in the acylation screening of the natural products. These included aliphatic and aromatic vinyl esters, which are commercially available. Amino acid vinyl esters that we synthesized were also screened during this investigation. Vinyl acid esters of the amino acid derivatives N, N-di-tert-butoxycarbonyl-L-lysine (67), N-tert-butoxycarbonyl-L-phenylalanine (76) and N-tert-butoxycarbonyl-L-valine (77) were all successfully synthesized using a palladium catalyst to carry out transvinylation reactions with vinyl acetate (29).

The initial aims of the investigation were to synthesize the vinyl acid esters of the basic amino acids arginine, histidine and lysine (61). Problems were encountered in synthesizing the vinyl esters of arginine and histidine derivatives. The arginine derivatives Nα-tert-butoxycarbonyl-Nω-Pbf-L-arginine (70) and Nα-tert-butoxycarbonyl-Nω-nitro-L-arginine (71) were restricted in their ability to anion exchange with the acetate groups of the catalyst palladium (II) acetate (Kosak and Johnson, 1993), due to their poor solubility in vinyl acetate (29). Two derivatives of histidine were also trialled for potential synthesis of vinyl esters; neither was successfully converted to the vinyl ester derivative. Nα, N(im)-di- tert-butoxycarbonyl-L-histidine (68), was unsuccessful due to the removal of the butoxycarbonyl group during the reaction (Sieber and Riniker, 1987). Nα-tert-butoxylcarbonyl-N(im)-tosyl-L-histidine (69) also had poor solubility in vinyl acetate (29), so similar problems were encountered with anion exchange. During this investigation it was possible to synthesize the vinyl ester of the basic amino acid lysine (67), using the derivative N, N-di-tert-butoxycarbonyl-L-lysine (64). 

Attempts were made to acylate the tert-butoxycarbonyl aminoglycoside, amikacin (57), with the synthesized amino acid vinyl esters (67, 76 and 77). A number of different proteases were screened, which were selected due to their previous applications in similar biotransformations. Small-scale reaction screening for acylations of the aminoglycoside derivative tetra-N-tert-butoxcarbonyl amikacin failed to identify any ‘hits’, in the solvent DMF. 

Failure to synthesize derivatives in DMF, led to the use of an alternative reaction media, containing both a phosphate buffer and triethylamine. The addition of phosphate buffer to the reaction media can be used to compensate for the potential loss of water from the enzyme. In the screening for tetra-N-tert-butoxcarbonyl amikacin (57) biotransformations, the polar solvent DMF was required in order to dissolve the substrates. The problem associated with using a polar solvent such as DMF is that it can strip the water molecules from the enzyme (Gorman and Dordick, 1992; MacNaughtan et al., 1993), which are essential to maintaining the tertiary structure. The second additive in the reaction media was triethylamine, which can enhance the acivity of enzymes and neutralise acidic species in the reaction media (Kise et al., 1988; Yamamoto and Kise, 1993). 

Despite studying the reactions in a variety of reaction media, with different proteases, it was not possible to synthesize the derivatives using a biotransformation approach. This meant that the collaboration with Dr. Phillip Young (Peninsula Medical School, Exeter, Devon) proved unsuccessful in providing derivatives that could be trialled in the upregulation of SMN2 in human fibroblast cells. Although this was disappointing, the collaboration is still active and the potential to synthesize derivatives (using either a biocatalysis or synthetic approach) is subject to further planning.

Similarly, it was not possible to acylate the flavonoid naringin (43), with the amino acid vinyl ester derivatives of lysine (67), phenylalanine (76) and valine (77). Alternatively, for biotransformations of naringin (43), aliphatic (24, 29 and 80) and aromatic (51 and 83) vinyl esters were screened with hydrolytic enzymes in non-aqueous reaction media. From small-scale reactions, numerous lipases were identified that carried out conversions of naringin (43) (acylations), which were identified by HPLC analysis. From the screening results, it was decided to scale-up the reactions using the P. stutzeri lipase. Scale-up of the reactions allowed for the isolation of products, which were synthesized in mg yields. Characterisation of the products, identified that P. stutzeri lipase was regioselective for the primary hydroxyl group of the glucose ring, which is a common occurrence in naringin (43) biotransformations (Kontogianni et al., 2001; 2003; Ishiharai et al., 2002; Gayot et al., 2003; Passicos et al., 2004; Katsoura et al., 2006; 2007).

The primary amino acid sequence of P. stutzeri lipase was acquired and a BLAST database search identified similar lipases, which share a high sequence identity. Sequence alignment of the amino acid sequences, using ClustalW allowed for the identification of conserved residues across the lipases. The structure of P. stutzeri lipase was modelled on the PDB deposited structure of the P. mendonica lipase (Bott and Wu, 2007). This allowed for the identification of the residues that form the catalytic triad (Blow et al., 1969), which were assigned as Ser149, His229 and Asp199. 










	There are numerous ways in which the work of this thesis could be continued. In future work the application of the P. stutzeri lipase in non-aqueous biotransformations could be fully investigated. In previous investigations with naringin (43) and other similar flavonoids, CALB, which is viewed as a classical enzyme, is often preferred for one-step acylations in non-aqueous reaction media. Therefore, for future work, the reaction yields of P. stutzeri lipase could be compared to those biotransformations previously carried out in the presence of CALB. As well as yields, it would also be ideal to compare the reaction kinetics of both enzymes in the same reactions. This would show if P. stutzeri lipase is a more effective catalyst, taking into account the length of time required for some non-aqueous biotransformations. 

	Further work also needs to be carried out, to study the possibility of catalysing the formation of aminoglycoside derivatives with amino acid vinyl esters. This could be done initially by further screening with additional proteases, to see if any are suitable for the acylation of the aminoglycosides in either of the reaction media (both aqueous and non-aqueous). Failure to identify a suitable protease, can lead to other techniques being employed, such as the modification of the enzyme catalyst. This could include the double approach of both directed evolution, by mutagenesis and further chemical modification of the mutant. This approach has previously increased the range of substrates accepted by proteases from species such as B. lentus (Berglund et al., 1997; Khumtaveeporn et al., 1999). This approach can reduce the restrictions of the enzyme’s active site, caused by steric clashes of larger substrates, such as the amino acid vinyl esters.

With the naringin derivatives (53, 81, 82, 84 and 85), it would be interesting to study their antioxidant activity at the biological level. The assay used in this investigation measures the ability of the derivatives (53, 81, 82, 84 and 85) to reduce Cu2+, the next step would be to study their properties in potentially protecting LDL. At the LDL level, lipophilic derivatives of existing antioxidants have been shown to incorporate themselves into the LDL structure (Chalas et al., 2001). If screening in LDL systems revealed higher antioxidant activity compared to naringin (43), then there would be the potential to screen these derivatives (53, 81, 82, 84 and 85) in animal models.




















Formula of trolox standard line of best fit:
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